Showing 4651-4660 of 5623 results for "".
- AstraZeneca’s COVID-19 Vaccine Produces Robust Immune Response in Elderlyhttps://modernod.com/news/astrazenecas-covid-19-vaccine-produces-robust-immune-response-in-elderly/2478462/AstraZeneca disclosed that its experimental COVID-19 vaccine AZD1222 triggered a robust immune response in elderly and older adults, similar to that previously seen in healthy study volunteers aged between 18 and 55. Adverse events associated with the vaccine, which is being co-developed with the
- UK Study Finds Evidence of Waning Antibody Immunity to COVID-19 Over Timehttps://modernod.com/news/uk-study-finds-evidence-of-waning-antibody-immunity-to-covid-19-over-time/2478463/Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found on Tuesday, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community, according to a Reuters
- AstraZeneca, J&J Say Their COVID-19 Vaccine Trials Back on Track in UShttps://modernod.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/AstraZeneca announced Friday that it has been cleared to restart its phase 3 COVID-19 vaccine trial in the US. The company, which is co-developing AZD1222 with the University of Oxford, had paused global testing of the vaccine candidate early last month after a UK participant fell ill with what i
- Visus Therapeutics Expands Clinical Advisory Board With Appointment of Renowned Ophthalmologistshttps://modernod.com/news/visus-therapeutics-expands-clinical-advisory-board-with-appointment-of-renowned-ophthalmologists/2478453/Visus Therapeutics announced the appointments of prominent ophthalmologists Marguerite McDonald, MD, Neda Shamie, MD, William Trattler, MD, and Lawrence Woodard, MD, to its clinical advisory board. Drs. McDonald, Shamie, Trattler and Woodard will lend their decades of experience in clinical pract
- Moderna Hits 30,000 Enrollment Target in Phase 3 Coronavirus Vaccine Trialhttps://modernod.com/news/moderna-hits-30000-enrollment-target-in-phase-3-coronavirus-vaccine-trial/2478450/Moderna announced that it has completed enrollment of 30,000 participants in the phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. More than 25,650 participants have so far received their second dose, and Moderna said it will decide whether to seek emergency-use autho
- Gilead’s Veklury Becomes First Treatment to Receive FDA Approval for COVID-19https://modernod.com/news/gileads-veklury-becomes-first-treatment-to-receive-fda-approval-for-covid-19/2478451/Gilead Sciences said Thursday that Veklury (remdesivir) has been approved by the FDA to treat hospitalized COVID-19 patients aged 12 years and older and weighing at least 40 kg, making it the first drug to gain full clearance in the US for the disease. The antiviral, which works by hindering the
- Rayner Launches Raytrace Premium IOL Calculator Update to Include Posterior Corneal Astigmatismhttps://modernod.com/news/rayner-launches-raytrace-premium-iol-calculator-update-to-include-posterior-corneal-astigmatism/2478444/Rayner announced the launch of their updated web-based premium IOL calculator, Raytrace. Developed in line with surgeon feedback, the new Raytrace version 3.5 includes the following improvements: Inclusion of Posterior Corneal Astigmatism (PCA) for more accurate toric IOL calculation
- Azura Ophthalmics Raises $20 Million for Registration Studies for Treatment of Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-raises-20-million-for-registration-studies-for-treatment-of-meibomian-gland-dysfunction/2478445/Azura Ophthalmics announced a $20 million financing to advance Azura’s lead product candidate AZR-MD-001 through a registration study for the treatment of meibomian gland dysfunction (MGD). Azura’s novel medicines in development are designed to address abnormal hyperkeratinization – the bu
- Volunteers to be Infected With Coronavirus in World’s First ‘Human Challenge’ Trialshttps://modernod.com/news/volunteers-to-be-infected-with-coronavirus-in-worlds-first-human-challenge-trials/2478437/Volunteers in London are to be infected with coronavirus early next year, in the world’s first COVID-19 “human challenge trials,” according to a Financial Times report. The project, first disclosed in the Financial Time
- Nevakar Enters into Licensing Agreement in China for NVK-002 for the Treatment of Myopia in Childrenhttps://modernod.com/news/nevakar-enters-into-licensing-agreement-in-china-for-nvk-002-for-the-treatment-of-myopia-in-children/2478434/Nevakar and Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO) announced have entered into an exclusive licensing agreement for the development and commercialization of Nevakar’s NVK-002 in Greater China, Hong Kong SAR, Macau SAR and Taiwan, South Korea and the Southeast Asian territories.